Solution
Industries
Resources
About
Beacon Search

MEGAKARYON CORP.

Company Snapshot

Founded: 2011
Entity Type: Private
Region: Japan
Headquarter: Kyoto, Japan
Key Geographics: Japan
Corporate Address: Kyoto Research Park 134 Minamimachi, Chudoji, Shimogyo-ku, Kyoto, 600-8813, Japan Tel. www.megakaryon.com

Company Overview

Megakaryon was founded in 2011 to commercialize the research results of Professor Nakauchi’s and Professor Eto’s research teams, whose work was identified as an Adaptable and Seamless Technology Transfer Program through Target-driven Research and Development project under the Japan Science and Technology Agency. By utilizing the regenerative potential of iPS cells, Megakaryon aims to produce high-quality platelets and other blood products that are safe, with a strong supply for demand, and that are affordable while independent of blood donations.

In April 2023, the first-ever human clinical trial using allogenic human iPSC-derived human leukocyte antigen (HLA) homozygous platelets was launched by Megakaryon Corp. In the second Japan Open Innovation competition in February 2020, Megakaryon Corp. and its partner firms were awarded the Minister of State for Science and Technology Policy Award.

MEGAKARYON CORP. In Reports

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028 at a CAGR of 9.1%.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate of 9.3%.

Induced Pluripotent Stem Cells: Global Markets

The global induced pluripotent stem cells (iPSC) market should reach $3.8 billion by 2024 from $2.4 billion in 2019 at a compound annual growth rate (CAGR) of 9.2% for the forecast period of 2019 to 2024. ...

View All Reports

MEGAKARYON CORP. In News

Induced Pluripotent Stem Cells Market Size Report, 2033 - Market Data Forecast

Market Data Forecast - Feb 19, 2025

Japan Needs Better Research Investment to Protect its Discoveries in iPS Cell Treatment - JAPAN Forward

JAPAN Forward - Mar 17, 2022

DewCell, Korea’s sole company developing stem cell-derived artificial platelet developer, aims for global market with world's first 50-liter bioreactor culture - 더바이오

더바이오 - Aug 12, 2025

The Japanese Are Developing Artificial Blood And It Could Potentially Do Away With Blood Donation - Indiatimes

Indiatimes - Jun 27, 2016

Read All News

Company's Business Segments

  • Products : The company generates revenue through products such as HLA homoplatelets, HLA-null platelets, and iMDF growth factor cocktail.

Applications/End User Industries

  • Research Institutions
  • Medical Institutions
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2025 BCC Research
Privacy Policy |Site Map|Terms & Conditions
AI Sentiment